You’re reading a free stock page from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More
Apellis Pharmaceuticals, Inc. Returns vs. S&P
|1 Year||5 Year||5 Year Annualized||Since IPO|
Apellis Pharmaceuticals, Inc. Company Info
Apellis Pharmaceuticals, Inc.
News & Analysis
Conflicting clinical trial results for the company's lead candidate are to blame.
The pre-commercial company is looking to take on a $23 billion industry leader. Promising late-stage clinical results suggest it may have a shot.
The company's lead drug candidate bested a competitor's therapy on a key endpoint in a phase 3 trial.
Pegcetacoplan is the first drug to beat Soliris in improving hemoglobin levels in PNH patients.
It looks like Apellis could have another competitor.
Keeping up with the news from major medical meetings has become a requirement for healthcare investors.
The company is issuing convertible debt to pad its balance sheet and fund late-stage clinical trials.
Here's what you need to know about the upgrades and bullish price targets analysts recently slapped on these drugmakers.
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.